SLC2A10 is expressed at low levels in colon adenocarcinoma, head and neck squamous cell carcinoma, kidney chromophobe, thyroid carcinoma, and uterine corpus endometrial carcinoma but is highly expressed in bladder cancer (Fig. 2B). Here, SLC2A10 is linked to urinary bladder cancer.